BioVersys AG (FRA:W33) EBIT: €-22.17 Mil (TTM As of Dec. 2025)


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.00
View Full Analysis

What is BioVersys AG EBIT?

BioVersys AG FRA:W33 -0.71% 7 EBIT is €-22.17 Mil as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 7/100.

BioVersys AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-11.01 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-22.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioVersys AG's annualized ROC % for the quarter that ended in Dec. 2025 was -251.55%. BioVersys AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3,413.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioVersys AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -21.03%.

BioVersys AG  (FRA:W33) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioVersys AG's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-22.712 * ( 1 - 0% )/( (10.525 + 7.533)/ 2 )
=-22.712/9.029
=-251.55 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=100.989 - 0.827 - ( 98.162 - max(0, 10.881 - 100.518+98.162))
=10.525

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=97.13 - 2.82 - ( 88.417 - max(0, 9.533 - 96.31+88.417))
=7.533

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

BioVersys AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-22.016/( ( (0.47 + max(-6.362, 0)) + (0.82 + max(-2.299, 0)) )/ 2 )
=-22.016/( ( 0.47 + 0.82 )/ 2 )
=-22.016/0.645
=-3,413.33 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.827 + 0 + 5.535)
=-6.362

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.924) - (2.82 + 0 + 6.403)
=-2.299

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioVersys AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-22.165/105.385
=-21.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG EBIT Related Terms

BioVersys AG EBIT Historical Data

* Premium members only.

The historical data trend for BioVersys AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG EBIT Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
EBIT
-18.94 -22.22

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
EBIT -10.21 -8.42 -11.16 -11.01

FRA:W33 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, BioVersys AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioVersys AG's EV-to-EBIT falls into.


FRA:W33
7GF Score
BioVersys AG FRA:W33
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-22.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-22.17 Mil mean?
BioVersys AG (FRA:W33) has a EBIT of €-22.17 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioVersys AG.
Is BioVersys AG's EBIT too high?
BioVersys AG's current EBIT is €-22.17 Mil. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's EBIT compare to VRTX and REGN?
BioVersys AG's EBIT of €-22.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioVersys AG. BioVersys AG's current EBIT is €-22.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current EBIT of €-22.17 Mil. The current EBIT is €-22.17 Mil. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current EBIT is €-22.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price